Ciprobay 200 mg/100 mL solution for infusion is indicated for the treatment of the following infections (see sections 4.4 and 5.1). Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy. Ciprobay XR 500 tablets are designed to release all of the dose prior to the tablet reaching the distal region of the small intestine. Following oral administration of the 500 mg modified release tablets, ciprofloxacin is almost completely absorbed. ADRs derived from clinical studies and post-marketing surveillance with Ciprobay (oral, intravenous and sequential therapy) sorted by categories of frequency are listed below. The frequency analysis takes into account data from both oral and intravenous administration of cipro oxacin. Ciprobay 500 mg is indicated for the treatment of the following infections (see sections 4.4 and 5.1). Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy. ADRs derived from clinical studies and post-marketing surveillance with Ciprobay(oral, intravenous and sequential therapy) sorted by categories of frequency are listed below. The frequency analysis takes into account data from both oral and intravenous administration of ciprofloxacin. CIPROBAY is an antibiotic belonging to the fluoroquinolone family. The active substance is ciprofloxacin. Ciprofloxacin works by killing bacteria that cause infections. It only works with specific strains of bacteria. Taking Ciprobay together with these medicines can influence the therapeutic effect of those medicines. It can also increase the probability of experiencing side effects.